Literature DB >> 17090397

Cytotoxicity of doxorubicin bound to poly(butyl cyanoacrylate) nanoparticles in rat glioma cell lines using different assays.

Berta Sanchez De Juan1, Hagen Von Briesen, Svetlana E Gelperina, Jörg Kreuter.   

Abstract

The cytotoxicity of doxorubicin bound to poly(butyl cyanoacrylate) nanoparticles (Dox-PBCA-NP) was investigated in the rat glioma cell lines GS-9L, F-98 and RG-2. MTT and LDH assays were used as cytotoxic assays. In general, the cytotoxicity of nanoparticle-bound doxorubicin (Dox) was enhanced compared to the free drug in solution. However, responses of the cell lines towards the drug effects were different. In the case of free Dox in solution, this difference correlated with different intracellular concentrations of Dox, which in turn, depended on the level of P-glycoprotein (P-gp) expression in these cell lines. Accordingly, the 9L gliosarcoma (GS-9L) cells, which appeared to be most resistant towards Dox, were characterized by the highest P-gp expression.Additionally, the influence of surfactants on the cytotoxic effect was investigated at different Dox concentrations. It was shown that the presence of polysorbate 80 (Tween 80) in the nanoparticle formulation significantly enhanced the cytotoxicity, whereas poloxamer 188 (Pluronic F68) and poloxamine 908 (Tetronic 908) had a negligible influence.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17090397     DOI: 10.1080/10611860600866872

Source DB:  PubMed          Journal:  J Drug Target        ISSN: 1026-7158            Impact factor:   5.121


  13 in total

1.  Microparticles prepared from biodegradable polyhydroxyalkanoates as matrix for encapsulation of cytostatic drug.

Authors:  A V Murueva; E I Shishatskaya; A M Kuzmina; T G Volova; A J Sinskey
Journal:  J Mater Sci Mater Med       Date:  2013-05-15       Impact factor: 3.896

2.  Opsonization, biodistribution, cellular uptake and apoptosis study of PEGylated PBCA nanoparticle as potential drug delivery carrier.

Authors:  Kiran Ramanlal Chaudhari; Mukesh Ukawala; Arehalli S Manjappa; Abhinesh Kumar; Piyush Kishor Mundada; Anil Kumar Mishra; Rashi Mathur; Jukka Mönkkönen; Rayasa S Ramchandra Murthy
Journal:  Pharm Res       Date:  2011-07-09       Impact factor: 4.200

Review 3.  In vitro assessments of nanomaterial toxicity.

Authors:  Clinton F Jones; David W Grainger
Journal:  Adv Drug Deliv Rev       Date:  2009-04-19       Impact factor: 15.470

4.  Enhanced anti-tumor effects of doxorubicin on glioma by entrapping in polybutylcyanoacrylate nanoparticles.

Authors:  Yuebin Zhang; Jia Yu; Lifeng Zhang; Jiabin Cai; Doute Cai; Chengjie Lv
Journal:  Tumour Biol       Date:  2015-09-24

5.  Controlled Drug Release and Chemotherapy Response in a Novel Acoustofluidic 3D Tumor Platform.

Authors:  Ioannis K Zervantonakis; Costas D Arvanitis
Journal:  Small       Date:  2016-03-31       Impact factor: 13.281

6.  The use of nanoparticle-mediated targeted gene silencing and drug delivery to overcome tumor drug resistance.

Authors:  Yogesh B Patil; Suresh K Swaminathan; Tanmoy Sadhukha; Linan Ma; Jayanth Panyam
Journal:  Biomaterials       Date:  2009-10-01       Impact factor: 12.479

7.  Small solutions for big problems: the application of nanoparticles to brain tumor diagnosis and therapy.

Authors:  D A Orringer; Y E Koo; T Chen; R Kopelman; O Sagher; M A Philbert
Journal:  Clin Pharmacol Ther       Date:  2009-02-25       Impact factor: 6.875

8.  Enhanced antitumor activity of doxorubicin in breast cancer through the use of poly(butylcyanoacrylate) nanoparticles.

Authors:  Laura Cabeza; Raúl Ortiz; José L Arias; Jose Prados; Maria Adolfina Ruiz Martínez; José M Entrena; Raquel Luque; Consolación Melguizo
Journal:  Int J Nanomedicine       Date:  2015-02-13

9.  Unraveling the cytotoxic potential of Temozolomide loaded into PLGA nanoparticles.

Authors:  Darshana S Jain; Rajani B Athawale; Amrita N Bajaj; Shruti S Shrikhande; Peeyush N Goel; Yuvraj Nikam; Rajiv P Gude
Journal:  Daru       Date:  2014-01-10       Impact factor: 3.117

Review 10.  Recent progress towards development of effective systemic chemotherapy for the treatment of malignant brain tumors.

Authors:  Hemant Sarin
Journal:  J Transl Med       Date:  2009-09-01       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.